At JY BioMed, we are advancing a dendritic cell (DC)-based vaccine platform designed to stimulate the body’s own immune system to recognize and attack tumor cells. Our approach leverages the natural antigen-presenting capabilities of mature dendritic cells, which play a central role in orchestrating adaptive immune responses. Through loading patient-specific or tumor-associated antigens onto autologous dendritic cells, we aim to generate targeted T cell activation that could lead to durable immune surveillance against cancer. Additionally, we are exploring dendritic cell-derived exosomes (DEX) as a next-generation, cell-free immunotherapeutic strategy to further enhance accessibility and scalability.

​

Our research focuses initially on solid tumors, including lung and pancreatic cancers, with potential future applications in broader immune modulation. All development activities are conducted under strict preclinical and early clinical frameworks, in alignment with global regulatory standards.